Latest news with #SimpleraSync
Los Angeles Times
18-05-2025
- Business
- Los Angeles Times
Bioscience Firms in Southern California Focus on Innovation & Collaboration
Southern California is one of the nation's leading life science hubs, led by the vast cluster of companies in San Diego County that focus on research and development. However, the sector is spread throughout the region with employers such as Amgen in Thousand Oaks and Edwards Lifesciences in Irvine featured among the top companies. New drug developments and delivery systems are some of the leading recent breakthroughs from local companies. Treatments have been created for a wide range of ailments, such as neuromuscular diseases, diabetes, eye disease and cancer, among others. Over the past few months, San Diego-based Avidity Biosciences Inc. reported multiple positive datasets from its three clinical-stage programs in rare muscle diseases. It is preparing for commercialization in anticipation of three potential products that could launch in close succession next year. 'Avidity's mission is to revolutionize the delivery of RNA therapeutics to make a profound difference in the lives of people living with serious rare diseases, many of whom have no or limited treatment options,' said Sarah Boyce, Avidity's chief executive. 'We plan to file our first biologics license application for our DMD44 drug candidate and accelerate commercial preparations for three potential product launches in rapid succession in all three rare neuromuscular diseases.' In Northridge, Medtronic Diabetes received approval from the Food and Drug Administration in April for its Simplera Sync sensor for use with the insulin delivery system MiniMed 780G. The new sensor is a disposable all-in-one that requires no fingerpricks. It plans a limited launch of the product this fall. 'We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,' said Que Dallara, president of Medtronic Diabetes, in a statement. Aliso Viejo-based Glaukos Corp. reported positive clinical updates in January for its iDose TR sustained-release procedural pharmaceutical platform. The company focuses on treatments of chronic eye diseases such as glaucoma, cataracts and diseases that impact the cornea and retina. In February, it followed up on their previous announcement with FDA acceptance of its new drug application for Epioxa, a therapy for keratoconus, which affects the cornea, and set an October goal for the FDA to review the treatment. In January, Agoura Hills-based A2 Biotherapeutics closed an $80-million Series C funding round that will be used for three clinical development programs of its precision cell therapies. Investors include The Column Group and Samsara BioCapital. 'We are excited by the initial clinical data from our lead programs, which we believe validates our proprietary logic-gate technology approach to solid tumor cancers,' said Jim Robinson, CEO of A2 Bio, in a statement. Other companies are expanding through collaboration. San Diego-based Amprion announced a collaboration with Mayo Clinic Laboratories to expand access to Amprion's SAAmplify test across the United States. The partnership is expected to improve diagnostic accuracy for neurodegenerative diseases. 'Amprion has developed early and accurate diagnostic tools for a range of neurodegenerative diseases, including Parkinson's, Lewy Body Dementia, and Multiple System Atrophy. Through this partnership, Amprion and Mayo are able to provide patients, physicians and families with one of the most comprehensive diagnostic offerings available,' said Russ Lebovitz, Amprion chief executive.
Yahoo
19-04-2025
- Business
- Yahoo
Medtronic (NYSE:MDT) Gains FDA Approval for Advanced Insulin Sensor in 2025
Medtronic recently announced the FDA approval for its Simplera Sync sensor, enhancing the MiniMed 780G system with significant technological advancements. Over the past week, Medtronic's share price remained flat, moving in line with broader market trends, which saw a 1.1% decline. Despite the positive product-related news, the share price was likely influenced by market dynamics, as the overall market context played a substantial role in Medtronic's performance. While the company's innovation could have supported its stock, it did little to counteract the prevailing trends affecting the market as a whole. Buy, Hold or Sell Medtronic? View our complete analysis and fair value estimate and you decide. Find companies with promising cash flow potential yet trading below their fair value. The recent FDA approval for Medtronic's Simplera Sync sensor, a significant enhancement to the MiniMed 780G system, highlights Medtronic's commitment to technological advancements. While the approval has yet to translate into immediate share price growth, it aligns well with Medtronic's long-term strategy of expanding its Cardiac Ablation Solutions and other innovative platforms such as the Hugo robotic system. Over the past year, Medtronic's total return, which includes both share price and dividends, increased by 7.44%. This occurs as the company continues to focus on emerging markets like India and innovations such as the Renal Denervation technique, positioning itself for future revenue increases. Comparatively, the company matched the US Medical Equipment industry, which returned 4.5% over one year and underperformed the broader US market return of 5.9% over the same period. The market's muted response to the FDA approval may have been influenced by current market dynamics, but the potential for higher future revenue and earnings remains. Analyst forecasts suggest revenue growth to US$38.2 billion by 2028, with earnings reaching US$6.1 billion, while Medtronic's shares trade at a discount compared to the analyst price target of US$96.83, with the current share price around 15% lower at US$82.7. If future clinical and regulatory milestones are met, the resulting revenue impact could help Medtronic achieve the forecasted growth and justify the analyst consensus price target. However, competitive pressures and regulatory dynamics remain variables to monitor closely. Examine Medtronic's past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:MDT. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
